Results 51 to 60 of about 2,554,026 (187)

Urate-Lowering Therapy in Moderate to Severe Chronic Kidney Disease [PDF]

The Permanente Journal, 2018
Hyperuricemia is an independent risk factor for progression of kidney disease.To determine whether lowering serum uric acid level (sUA) to below 6 mg/dL (target) improves mild to moderate chronic kidney disease (CKD) and whether CKD stage influences the benefit of lowering sUA to target.Retrospective epidemiologic cohort study conducted over 8 years ...
Gerald, Levy, Jiaxiao M, Shi, T Craig, Cheetham, Nazia, Rashid   +3 more
openaire   +2 more sources

Caregiver Perspectives on the Burden of Disease and Treatment in Uncontrolled Gout

Arthritis Care &Research, EarlyView.
Objective Uncontrolled gout (UG) refers to persistently elevated serum urate (SU) levels >6 mg/dL and ongoing gout symptoms despite use of urate‐lowering therapy (ULT). The objective of this study was to evaluate the burden associated with informal caregiving for individuals with UG.
Angelo Gaffo, Bhavisha Desai, Abiola Oladapo, Nana Kragh, Rebekah Zincavage, Brad Padilla, Naomi Schlesinger   +6 more
wiley   +1 more source

Evaluating Serum Urate Monitoring amongst Older Adults with Gout Initiating Urate Lowering Therapy in Ontario, Canada [PDF]

, 2023
Serum urate (SUA) monitoring plays an important role in gout management. This thesis examined whether older adults with gout received SUA monitoring after initiating urate lowering therapy (ULT).
Kwok, Timothy Shun Him
core   +1 more source

Impact of Hyperuricemia and Urate-Lowering Agents on Cardiovascular Diseases

Clinical Medicine Insights: Cardiology
The association between hyperuricemia and cardiovascular diseases has been studied for many years. Research has shown a link between high uric acid levels and increased risk of including coronary artery disease hypertension and other cardiovascular ...
Franklin Sosa, Mohammed Shaban, Jose Lopez, Gustavo J. Duarte, Swati Jain, Asma Khizar, Timothy Vittorio, Rishabh Mishra, Miguel Rodriguez Guerra   +8 more
doaj   +1 more source

Problems of adherence to therapy in patients with gout in real clinical practice

Consilium Medicum
Aim. To evaluate treatment adherence among patients with gout. Materials and methods. One hundred and thirty-eight patients with gout were examined in the Dzhanelidze Saint Petersburg Research Institute of Emergency Care; 89.9% of them are men and 10 ...
Elena V. Shchemeleva, Elena A. Skorodumova   +1 more
doaj   +1 more source

A rationally grounded approach to treating gout with regard to its onset and course and the presence of comorbidity according to the European League against Rheumatism (EULAR 2016) recommendations

Терапевтический архив, 2017
The review analyzes in detail the management of gout, which takes into account its onset and course and the presence of comorbidity. Emphasis is placed on drug and non-drug treatments and urate-lowering therapy in patients with kidney dysfunction.
V V Tsurko, M A Gromova
doaj   +1 more source

Principles of urate-lowering therapy: eight steps to success

Современная ревматология, 2023
Treatment of such a serious systemic disease as gout is often carried out incorrectly, despite the presence of a large number of recommendations and drugs.
O. V. Zhelyabina, M. S. Eliseev, A. M. Lila   +2 more
doaj   +1 more source

Harnessing Large‐Scale Multi‐Omics Data for Risk Prediction and Deep Phenotyping of Valvular Heart Diseases in the General Population

Advanced Science, EarlyView.
Large‐scale UK Biobank analyses identify clinical and proteomic signatures for early prediction of valvular heart disease and its subtypes. Proteins add predictive value for VHD, AVS, and MVR, with outcome‐specific compact panels showing translational potential. Multi‐layer evidence highlights matrix remodeling, protease regulation, immune inflammation,
Zhihao Jiang, Yang Liu, Mingyu Song, Ning Chen, Canqing Yu, Jun Lv, Eric Yuk Fai Wan, Lu Qi, Liming Li, Dianjianyi Sun, Bang Zheng   +10 more
wiley   +1 more source

Membrane‐Active Peptide Protects Against Inflammation by Targeting NLRP3 Activation at the Trans‐Golgi Network

Advanced Science, EarlyView.
The membrane‐active peptide Pep19‐2.5 reduces harmful inflammation by blocking activation of the NLRP3 inflammasome at trans‐Golgi network membranes. By targeting key membrane interactions, Pep19‐2.5 suppresses inflammatory IL‐1β production and alleviates allergic airway inflammation in mice, leading to reduced immune cell infiltration and improved ...
Jonas Engelhardt, Nico Kirsch, Aileen Kerfin, Lars P. Lunding, Dominic Ferber, Hannes Buthmann, Ilka Schreier, Carlotta Bosio, Ann‐Kathrin Dobbelstein, Anna Klawonn, Rebecca C. Coll, Lena Bauernhofer, Sandro Keller, Matthias Geyer, Michael Wegmann, Andra B. Schromm, Günther Weindl   +16 more
wiley   +1 more source

Urate lowering therapy in primary care: rheum for improvement [PDF]

Exploration of Musculoskeletal Diseases
Primary care physicians (PCPs) play a critical role in the management of gout worldwide. However, significant gaps in gout care persist, underscoring the need for improved approaches to its management.
Emilie Schurenberg, Edward M. Huddleston, Kenneth G. Saag   +2 more
doaj   +1 more source